Indefinite Delivery Contract 75D30122D14072
Award Date
7/1/22
Last Date to Order
6/30/23
Federal Agency
CDC Pittsburgh
Awardee
Merck Sharp & Dohme LLC
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Multiple
Primary Consortia Member
Not listed
Similar IDVs
The Centers for Disease Control and Prevention awarded multiple indefinite delivery contracts to Merck Sharp & Dohme LLC for adult vaccines. The contracts have a potential value of $83,485,760 and a period of performance from July 1, 2021 to June 30, 2022. Merck will provide 13 standard adult vaccines including hepatitis A, hepatitis B, pneumococcal polysaccharide, tetanus/diphtheria toxoids, herpes zoster, measles/mumps/rubella, meningococcal conjugate, human papillomavirus, and...
The Centers for Disease Control and Prevention awarded multiple indefinite delivery contracts under a competitive solicitation to purchase standard adult vaccines. The contracts hold a potential value of $102.6 million and require the awarded vendors to provide 13 vaccines to support immunization programs administered by state and local health authorities pursuant to Section 317(j) of the Public Health Service Act. Vaccines include hepatitis A and B, pneumococcal, tetanus/diphtheria, herpes...
The Centers for Disease Control and Prevention awarded multiple indefinite-delivery, indefinite-quantity contracts valued at up to $25,350,000 to supply adult vaccines for the period of July 1, 2023 through June 30, 2024. The prime contractor is VBI Vaccines (Delaware) Inc. The contracts aim to procure minimum and maximum quantities of 12 adult vaccines, including hepatitis A, hepatitis B, pneumococcal polysaccharide, tetanus and diphtheria toxoids, herpes zoster, measles, mumps and rubella,...
The Centers for Disease Control and Prevention awarded multiple indefinite-delivery, indefinite-quantity contracts to Pfizer Inc. for the delivery of various adult vaccines. The contracts have a one year period of performance from July 1, 2022 to June 30, 2023 and a combined potential value of $62.2 million.
Through these contracts, Pfizer will provide 12 standard adult vaccines to the CDC including hepatitis A & B, pneumococcal, tetanus/diphtheria, herpes zoster, Tdap, MMR,...
The Centers for Disease Control and Prevention (CDC) has awarded a multiple-award Indefinite Delivery Contract (IDC) valued up to $69,520,654.32 to Merck Sharp & Dohme LLC, doing business as Merck, for the supply of various adult vaccines. The contract has a period of performance from July 1, 2024 to June 30, 2025 and does not involve any set-aside designations.
The IDC requires Merck, as a pharmaceutical manufacturer, to provide a wide range of adult vaccines including Hepatitis A,...
The Centers for Disease Control and Prevention awarded multiple indefinite delivery contracts to purchase adult vaccines in support of state immunization programs. The contracts have a potential value of $1,727,800 and a period of performance from July 1, 2022 to June 30, 2023. Grifols USA LLC is a prime contractor.
The original solicitation sought to purchase 12 standard adult vaccines with minimum and maximum order quantities ranging from 100 to 1,000,000 doses per vaccine. Vaccines must...
The Department of Health and Human Services Centers for Disease Control and Prevention (CDC) awarded a multiple award indefinite delivery contract to Glaxosmithkline, LLC, a foreign-owned pharmaceutical company, to supply a variety of adult vaccines including hepatitis, pneumococcal, tetanus, herpes zoster, measles, meningococcal, and human papillomavirus vaccines. The $232.5 million contract has a period of performance from July 1, 2023 to June 30, 2024 and will support adult immunization...
The Centers for Disease Control and Prevention (CDC) has awarded Pfizer Inc. an Indefinite Delivery Contract (IDC) for the supply of various adult vaccines to support immunization programs under Section 317(j) of the Public Health Service Act. The $103,060,230.33 contract, which runs from July 1, 2023 to June 30, 2024, covers a range of vaccines including hepatitis A, hepatitis B, pneumococcal polysaccharide, tetanus and diphtheria toxoids, herpes zoster, measles-mumps-rubella, meningococcal...
The Centers for Disease Control and Prevention awarded multiple indefinite delivery contracts to Sanofi Pasteur Inc. for the procurement of adult vaccines. The contracts have a potential value of $39.08 million to supply 13 standard adult vaccines over a one year period from July 1, 2021 through June 30, 2022. Vaccines will be delivered within 15 business days of order to support immunization programs in 50 state health departments and large cities, as provided under Section 317(j) of the...
Sanofi Pasteur Inc. was awarded an indefinite delivery contract by the Department of Health and Human Services Centers for Disease Control and Prevention to supply various adult vaccines. The contract is a multiple award with a potential value of $42.4 million and a period of performance from July 1, 2023 through June 30, 2024.
The originating solicitation sought proposals for contracts to provide approximately 1.5 to 3 million doses of 12 different adult vaccines in support of the CDC's...